Previous 10 |
Amicus Therapeutics (NASDAQ: FOLD ) initiated with Overweight rating and $20 (76% upside) price target at Cantor Fitzgerald. Shares up 2% premarket. More news on: Amicus Therapeutics, Inc., Intercept Pharmaceuticals, Allergan plc, Healthcare stocks news, Stocks on the move, , ...
Intercept Rallies Ahead Of NASH Readout Perhaps in anticipation of NASH data, shares of Intercept ( ICPT ) continue to rally and, just recently, broke strong technical resistance: Introduction Intercept's obeticholic acid should see phase 3 NASH data this quarter. Although analysts ...
The Update On Intercept Pharmaceuticals Intercept Pharmaceuticals ( ICPT ) is a well-recognized commercial stage mid-cap ($3.29B) liver therapeutics company. Its lead drug candidate is obeticholic acid ((OCA)), a prototype FXR agonist. OCA is currently in two Phase 3 clinical trials for N...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...